Noticias y Actividades de Biocryst Pharmaceuticals

Biocryst Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Biocryst Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización BCRX (US).

Ver el organigrama con sus 24 ejecutivos principales

Biografías más buscadas en Biocryst Pharmaceuticals

• Jon Stonehouse, President, Chief Executive Officer, Interim Chief ...
• Amy McKee, Director
• Alan Levin, Director

Recientes movimientos de ejecutivos en Biocryst Pharmaceuticals

• Jon Stonehouse que ha sido President, Chief Executive Officer, Director, pasa a ser President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Accounting Officer and Director  (noticia publicada el 11 de abril de 2025).
• Anthony Doyle, Senior Vice President and Chief Financial Officer, abandonará la empresa el 9 de abr.. de 2025  (noticia publicada el 6 de marzo de 2025).
• Donald Fong que ha sido Vice President of Ophthalmology Therapeutic Area, ha ascendido a Chief Medical Officer  (noticia publicada el 6 de septiembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Biocryst Pharmaceuticals.

Biocryst Pharmaceuticals tiene 2.351 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Genus (Reino Unido).

Popular M&A news in Biotecnología

• Transcarent and Accolade have merged  (publicado el 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).

Otros contactos sugeridos en el sector Biotecnología

• Kristina Burow - Director en Scholar Rock
• Steven Gillis - Chairman of the Board en VBI Vaccines
• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Biocryst Pharmaceuticals

• BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones | BioCryst Pharmaceuticals
• BioCryst Resumes Enrollment in BCX9930 Clinical Program | BioCryst Pharmaceuticals
• BioCryst Resumes Enrollment in BCX9930 Clinical Program | BioCryst Pharmaceuticals
• BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones | BioCryst Pharmaceuticals
• BioCryst to Report Second Quarter 2022 Financial Results on August 4 | BioCryst Pharmaceuticals
• BioCryst to Report Second Quarter 2022 Financial Results on August 4 | BioCryst Pharmaceuticals
• BioCryst to Present at Upcoming Investor Conference | BioCryst Pharmaceuticals
• BioCryst to Present at Upcoming Investor Conference | BioCryst Pharmaceuticals
• BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) | BioCryst Pharmaceuticals
• BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) | BioCryst Pharmaceuticals
• View more press releases Close

Redes sociales sobre Biocryst Pharmaceuticals

• Biocryst Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Biocryst Pharmaceuticals en LinkedIn, Twitter y YouTube